This combination blend pairs Semax and Selank, two structurally related peptides derived from ACTH and tuftsin sequences, both studied extensively in Russian neuropharmacology research. Semax is researched for its potential effects on memory, focus, and neuroprotection, while Selank is studied for its anxiolytic (stress-modulating) properties and influence on the immune-neuroendocrine axis. Together, this blend is of interest to researchers exploring cognitive enhancement alongside stress-response regulation. Manufactured to strict quality standards and verified through third-party lab testing (COA available on request).
For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
This combination blend pairs Semax and Selank, two structurally related peptides derived from ACTH and tuftsin sequences, both studied extensively in Russian neuropharmacology research. Semax is researched for its potential effects on memory, focus, and neuroprotection, while Selank is studied for its anxiolytic (stress-modulating) properties and influence on the immune-neuroendocrine axis. Together, this blend is of interest to researchers exploring cognitive enhancement alongside stress-response regulation. Manufactured to strict quality standards and verified through third-party lab testing (COA available on request).
For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Coming soon
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
on orders over $200
plain and unbranded packaging
256-bit SSL
Not a researcher? Exit
